Spermidine, Hesperidin and AM3 Combo Tested for Immune Function and Biological Age
An 8-week RCT examines whether a triple supplement stack can improve immune markers and lower biological age in healthy adults.
Summary
This completed clinical trial tested whether a daily two-capsule supplement combining AM3 (Inmunoferon), hesperidin, and spermidine could improve immune function and reduce biological age over eight weeks in healthy volunteers. Participants were randomized to either the active supplement or a visually identical placebo, with full blood panels drawn at baseline and at week eight. The three ingredients each carry distinct biological rationales: spermidine induces autophagy and has shown lifespan extension in animal models; hesperidin is a flavonoid with anti-inflammatory and senolytic properties; and AM3 is a glycoprotein immunomodulator used in Spain. By measuring both immunological markers and a biological age estimate before and after intervention, the trial aims to link supplement-driven immune changes to measurable aging biomarkers in otherwise healthy people.
Detailed Summary
Extending healthy lifespan requires interventions that can measurably shift the biology of aging — not just in diseased populations but in healthy adults proactively seeking to preserve function. This trial addresses exactly that challenge by combining three compounds with distinct but complementary mechanisms into a single supplement and asking whether eight weeks of daily use can move the needle on immunity and biological age simultaneously.
The study is an industry-sponsored, randomized, placebo-controlled interventional trial conducted in healthy adults. Participants received two capsules daily of either Inmunoferon (containing AM3, hesperidin, and spermidine) or a matching placebo for eight weeks. Blood samples were collected at baseline and at the eight-week endpoint to assess immune status and estimate biological age.
The three active ingredients each carry strong mechanistic rationale. Spermidine is a polyamine that stimulates autophagy — the cellular recycling process that declines with age and whose restoration extends lifespan in multiple model organisms. Hesperidin, a citrus flavonoid, has demonstrated anti-inflammatory, antioxidant, and potential senolytic activity. AM3 is a glycoprotein immunomodulator with established use in immunocompromised patients in Spain, capable of enhancing innate and adaptive immune responses.
The trial's primary value lies in pairing immunological endpoints with a biological age measurement, allowing researchers to ask whether supplement-driven immune improvements correlate with a younger biological profile. This is a relatively rare design in supplement research and, if positive, would provide both mechanistic and functional evidence for the stack.
Important caveats apply. The trial was sponsored by the manufacturer of Inmunoferon, raising potential bias concerns. The eight-week window is short for detecting durable aging-related change. Full results have not yet been published in a peer-reviewed journal, and this summary is based on the ClinicalTrials.gov abstract only, meaning effect sizes, statistical significance, and safety data remain unavailable.
Key Findings
- Spermidine, hesperidin, and AM3 were combined in a single oral supplement and tested against placebo in healthy adults.
- Biological age was measured before and after 8 weeks, providing a rare aging-biomarker endpoint in supplement research.
- The 8-week double-blind design with blood sampling at two time points allows clean pre-post comparison of immune markers.
- Trial is now completed; peer-reviewed results are pending and will determine whether the combination shows measurable benefit.
- Spermidine's autophagy induction, hesperidin's anti-inflammatory effects, and AM3's immunomodulation offer complementary longevity mechanisms.
Methodology
Randomized, placebo-controlled, double-blind interventional trial in healthy adults sponsored by Industrial Farmacéutica Cantabria. Participants took two capsules per day for 8 weeks, with complete blood draws at baseline and week 8 to assess immune markers and biological age. Phase was listed as not applicable, and the trial is now marked completed.
Study Limitations
This summary is based on the ClinicalTrials.gov abstract only, as the full study data and peer-reviewed publication are not yet available; effect sizes, p-values, and adverse events are unknown. The trial is industry-sponsored by the supplement's manufacturer, which introduces potential conflict-of-interest bias. The 8-week duration is relatively short to demonstrate durable changes in biological aging biomarkers.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: